Pan-intestinal Capsule Endoscopy Versus Colonoscopy in Iron Deficiency Anemia or Overt GI Bleeding

Overview

The authors hypothesize that in patients with iron deficiency anemia or gastrointestinal bleeding, pan-intestinal capsule endoscopy is a safe and well tolerated procedure that may improve diagnostic yield comparatively to the current standard invasive colonoscopy.

Full Title of Study: “Pan-intestinal Capsule Endoscopy Versus Conventional Colonoscopy in Iron Deficiency Anemia or Overt GI Bleeding: a Prospective Cohort Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Diagnostic
    • Masking: Double (Care Provider, Investigator)
  • Study Primary Completion Date: September 20, 2022

Detailed Description

Patients presenting with iron deficiency anemia (IDA) or overt GI bleeding are often submitted to conventional upper GI endoscopy and colonoscopy, followed by small bowel capsule endoscopy if diagnosis remains elusive. Recently, however, the possibility of performing pan-intestinal endoscopy using a video capsule that evaluates both the small bowel and the colon in a single non-invasive examination, opens new perspectives for the management of those conditions, particularly when the initial upper GI endoscopy has been non-diagnostic. The authors hypothesize that performing early pan-intestinal capsule endoscopy strategy may allow, in a safe and well tolerated manner, to identify which patients would benefit of further interventions, such as colonoscopy or invasive enteroscopy, guided by findings pre-identified at capsule examination. The study aims to evaluate whether pan-intestinal capsule endoscopy is superior to the current standard strategy of conventional colonoscopy after non-diagnostic upper endoscopy in patients with IDA or overt GI bleeding, regarding diagnostic yield, safety and tolerability.

Interventions

  • Diagnostic Test: Pan-intestinal capsule endoscopy
    • Patients with iron deficiency anemia or overt GI bleeding with non-diagnostic upper GI endoscopy will be submitted to same-day pan-intestinal capsule endoscopy using PillCam Crohn’s Capsule (Medtronic) followed by conventional colonoscopy under propofol sedation

Arms, Groups and Cohorts

  • Experimental: Pan-intestinal capsule endoscopy
    • PillCam Crohn’s capsule protocol
  • Active Comparator: Conventional colonoscopy
    • Same-day colonoscopy under propofol sedation

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with at least one potentially bleeding lesion detected in small bowel and/or colon
    • Time Frame: 2 weeks
    • Potentially bleeding lesions include tumors, angiectasias, erosions, ulcers, diverticula or active bleeding

Secondary Measures

  • Safety: number of participants with any procedure-related adverse events
    • Time Frame: 2 weeks
    • Adverse events include capsule retention, bowel preparation-related (nausea, vomiting, dizziness, seizures, abdominal pain or bloating), bleeding, perforation or cardiopulmonary complications
  • Patient’s preference: number of participants preferring capsule endoscopy or colonoscopy
    • Time Frame: 2 weeks
    • Questionnaire regarding preference based on overall experience and perception of the strengths and limitations of each procedure

Participating in This Clinical Trial

Inclusion Criteria

  • Patients from external consultation, hospital ward or urgency department, with suspected GI bleeding presenting in the occult form as IDA (Hb <12.0 g/dL in female gender or <13.0 g/dL in male gender) and/or overt GI bleeding presenting as melaena and/or haematochezia, and with prior non-diagnostic upper GI endoscopy (esophagogastroduodenoscopy, EGD) Exclusion Criteria:

1. Lack of informed consent 2. Suspected lesions at index EGD that could justify the anemia or digestive bleeding 3. Known history of gastroparesis or bowel dysmotility 4. Known or suspected intestinal stricture 5. Female patients with potential gynaecological source of bleeding causative of the clinical condition 6. Patients with severe malnutrition 7. Patients unable to walk at least for short periods and/or with neurological and/or psychiatric condition potentially favouring protocol deviations 8. Allergy or contra-indications to any of the drugs or products used in the study 9. Pregnancy or breastfeeding

Gender Eligibility: All

Minimum Age: 8 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hospital da Senhora da Oliveira
  • Collaborator
    • Medtronic
  • Provider of Information About this Clinical Study
    • Principal Investigator: Bruno Rosa, MD – Hospital da Senhora da Oliveira
  • Overall Official(s)
    • Bruno Rosa, MD, Principal Investigator, Gastroenterology Department, Hospital da Senhora da Oliveira – Guimarães, Portugal

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.